Dublin, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The "Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters (Cardiovascular Devices) - Medical Devices Pipeline Product Landscape, 2021" report has ...

The global percutaneous transluminal coronary angioplasty (PTCA) balloon catheters market was estimated to be $1,201.23 million in 2021 and is estimated to reach $1,848.76 million in 2031 with an ...

SINGAPORE, Nov. 11, 2022 /PRNewswire/ -- Genesis MedTech Group announced today that the Food and Drug Administration (FDA) has approved the Chocolate Touch® Drug-coated Balloon PTA Catheter, developed ...

DUBLIN--(BUSINESS WIRE)--The "Global Percutaneous Transluminal Angioplasty (PTA) Market (2024 Edition): Analysis By Product Type (Balloon Catheters, Stents, Guidewires, Others), By Application, By End ...

The Percutaneous Transluminal Angioplasty Balloons Market was valued at US$ 2.1 Bn in 2022 and is projected to grow at a CAGR of 5.4% from 2022 to 2031, reaching more than US$ 3.5 Bn by 2031. Rising ...

Low-profile, high-pressure balloon offers physicians exceptional performance in a single platform for peripheral angioplasty procedures NATICK, Mass., Boston Scientific Corporation today announced the ...

The global percutaneous transluminal angioplasty (PTA) balloons market was valued at approximately US$ 2.1 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 5.4%, ...

Covidien's Fortrex percutaneous transluminal angioplasty balloon catheter--Courtesy of Covidien Covidien ($COV) today announced FDA 510(k) clearance for its Fortrex ...

WAYNE, Pa.--(BUSINESS WIRE)--Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the peer-reviewed publication of its Tack ...

Dublin, Oct. 21, 2022 (GLOBE NEWSWIRE) -- The "Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheters: Global Strategic Business Report" report has been added to ...

LEIPZIG, Germany — One-year results of the ACHILLES trial show treatment of infrapopliteal arterial disease with a sirolimus-eluting stent (SES) is more efficacious and just as safe when compared with ...